172 related articles for article (PubMed ID: 18422767)
1. The discovery and application of gene fusions in prostate cancer.
Morris DS; Tomlins SA; Montie JE; Chinnaiyan AM
BJU Int; 2008 Aug; 102(3):276-82. PubMed ID: 18422767
[TBL] [Abstract][Full Text] [Related]
2. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
Shah RB; Chinnaiyan AM
Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877
[TBL] [Abstract][Full Text] [Related]
3. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].
Guo XQ; Gui YT; Cai ZM
Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967
[TBL] [Abstract][Full Text] [Related]
4. [TMPRSS2-ETS gene fusion in prostate cancer].
Perner S; Schmidt FH; Hofer MD; Kuefer R; Rubin M
Urologe A; 2007 Jul; 46(7):754-60. PubMed ID: 17458530
[TBL] [Abstract][Full Text] [Related]
5. Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study.
Sun QP; Li LY; Chen Z; Pang J; Yang WJ; Zhou XF; Qiu JG; Su ZL; He D; Gao X
J Mol Diagn; 2010 Sep; 12(5):718-24. PubMed ID: 20616363
[TBL] [Abstract][Full Text] [Related]
6. ETS gene fusions in prostate cancer: from discovery to daily clinical practice.
Tomlins SA; Bjartell A; Chinnaiyan AM; Jenster G; Nam RK; Rubin MA; Schalken JA
Eur Urol; 2009 Aug; 56(2):275-86. PubMed ID: 19409690
[TBL] [Abstract][Full Text] [Related]
7. Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer.
Rubin MA; Chinnaiyan AM
Lab Invest; 2006 Nov; 86(11):1099-102. PubMed ID: 16983328
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
9. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.
Pflueger D; Terry S; Sboner A; Habegger L; Esgueva R; Lin PC; Svensson MA; Kitabayashi N; Moss BJ; MacDonald TY; Cao X; Barrette T; Tewari AK; Chee MS; Chinnaiyan AM; Rickman DS; Demichelis F; Gerstein MB; Rubin MA
Genome Res; 2011 Jan; 21(1):56-67. PubMed ID: 21036922
[TBL] [Abstract][Full Text] [Related]
10. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.
Tomlins SA; Mehra R; Rhodes DR; Smith LR; Roulston D; Helgeson BE; Cao X; Wei JT; Rubin MA; Shah RB; Chinnaiyan AM
Cancer Res; 2006 Apr; 66(7):3396-400. PubMed ID: 16585160
[TBL] [Abstract][Full Text] [Related]
11. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
12. Retention of Interstitial Genes between
Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
[No Abstract] [Full Text] [Related]
13. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
Merdan S; Tomlins SA; Barnett CL; Morgan TM; Montie JE; Wei JT; Denton BT
Cancer; 2015 Nov; 121(22):4071-9. PubMed ID: 26280815
[TBL] [Abstract][Full Text] [Related]
14. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
[TBL] [Abstract][Full Text] [Related]
15. Recurrent gene fusions in prostate cancer: their clinical implications and uses.
Hessels D; Schalken JA
Curr Urol Rep; 2013 Jun; 14(3):214-22. PubMed ID: 23625457
[TBL] [Abstract][Full Text] [Related]
16. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
17. ETS gene fusions in prostate cancer.
Clark JP; Cooper CS
Nat Rev Urol; 2009 Aug; 6(8):429-39. PubMed ID: 19657377
[TBL] [Abstract][Full Text] [Related]
18. Recurrent gene fusions in prostate cancer.
Kumar-Sinha C; Tomlins SA; Chinnaiyan AM
Nat Rev Cancer; 2008 Jul; 8(7):497-511. PubMed ID: 18563191
[TBL] [Abstract][Full Text] [Related]
19. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
[TBL] [Abstract][Full Text] [Related]
20. ETS gene fusions and prostate cancer.
Huang W; Waknitz M
Am J Transl Res; 2009 May; 1(4):341-51. PubMed ID: 19956446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]